Compare General Mills, Inc. (GIS) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Organon & Co. Common Stock — how do they compare? General Mills, Inc. trades at $32.31 (market cap $17.02B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: General Mills, Inc. is far larger — about 4.7× Organon & Co. Common Stock's market cap, and General Mills, Inc. pays the higher dividend (7.67%). Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 107 Days and Organon & Co. Common Stock for 0 Days on average.
| GIS | OGN | |
|---|---|---|
Market Cap | $17.02B | $3.62B |
Volume | 7,979,067 | 2,892,999 |
Sector | Consumer Staples | Health |
52-Week High | $49.18 | $13.81 |
52-Week Low | $31.67 | $5.70 |
Typical Hold Time | 107 Days | 0 Days |
Enterprise Value | $30.20B | $11.04B |
Dividend Yield | 7.67% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $31.83, down 2.66% amid bearish technical signals and negative profitability metrics. The stock shows mixed earnings performance with a recent Q2 beat but Q4 miss, while revenue has declined from $20.1B in 2023 to $19.5B in 2025. Analyst consensus remains cautious with 61% hold ratings, though the $36 price target suggests 13% upside potential. Recent CEO transition and dividend declaration provide stability signals despite profitability challenges.
The outlook remains challenged by declining margins and negative ROE/ROA, though attractive valuation (P/E 9.2) and dividend yield offer value appeal. Key risks include continued revenue pressure, margin compression, and high debt levels at 45% of assets. Upside depends on successful execution of the $3B savings plan and international growth initiatives.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
